UPDATE: Credit Suisse Initiates Regeneron Pharmaceutical at Outperform
Credit Suisse initiales coverage on Regeneron Pharmaceutical (NASDAQ: REGN) with an Outperform rating and a $187 price target.
Credit Suisse said, "The primary value driver remains quarterly sales of Eylea. Proposed legislation regulating compounding pharmacies, a permanent J code in January and the launch in RVO could all help boost sales. Competitor data for Amgen's AMG145 (anti-PCSK9) and Ophthotech's Fovista have all recently been disclosed, and key clinical data for Regeneron are limited in the near term."
Regeneron Pharmaceutical closed at $144.90 on Monday.
Latest Ratings for REGN
|Feb 2016||Leerink Swann||Initiates Coverage on||Outperform|
|Jan 2016||Canaccord Genuity||Downgrades||Buy||Hold|
|Jan 2016||Chardan Capital||Downgrades||Neutral||Sell|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.